INTRODUCTION
T he prolactin releasing peptide, or PrRP, is a member of the RF-amide peptide family and is mainly expressed in the medulla oblongata, brainstem, and hypothalamus. [1] [2] [3] It is the endogenous agonist of the PrRP receptor (also known as GPR10 or hGR3) and interacts with nanomolar binding affinities. 4 Furthermore, it has some affinity for other RF-amide and FF-amide receptors, such as the hNPFF2 receptor. 5 These receptors are integral membrane proteins that belong to the large family of G-protein coupled receptors, or GPCRs, which constitute about one-third of all major drug targets. 6 While the original function of PrRP was proposed to be the stimulation of prolactin secretion, 4, 7 it is now generally accepted that this is not the primary function of the peptide. Increasing evidence indicates that PrRP plays a significant role in food intake and body weight homeostasis. 8 Indeed, intracerebroventricular administration of PrRP with leptin in rats resulted in body
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ABSTRACT:
The prolactin releasing peptide (PrRP) is involved in regulating food intake and body weight homeostasis, but molecular details on the activation of the PrRP receptor remain unclear. C-terminal segments of PrRP with 20
(PrRP20) and 13 (PrRP8-20) amino acids, respectively, have been suggested to be fully active. The data presented herein indicate this is true for the wildtype receptor only; a 5-10-fold loss of activity was found for PrRP8 -20 compared to PrRP20 at two extracellular loop mutants of the receptor. To gain insight into the secondary structure of PrRP, we used CD spectroscopy performed in TFE and SDS. Additionally, previously reported NMR data, combined with ROSETTANMR, were employed to determine the structure of amidated PrRP20. The structural ensemble agrees with the spectroscopic data for the full-length peptide, which exists in an equilibrium between a-and 3 10 -helix. We demonstrate that PrRP8-20's reduced propensity to form an a-helix correlates with its reduced biological activity on mutant receptors.
Further, distinct amino acid replacements in PrRP significantly decrease affinity and activity but have no influence on the secondary structure of the peptide. We conclude that formation of a primarily a-helical Cterminal region of PrRP is critical for receptor activation.
weight gain. 9 In addition, both PrRP-and PrRP receptor-deficient mice were shown to develop late-onset obesity. 10 PrRP exists in two isoforms: PrRP20 and PrRP31, which consist of 20 and 31 residues, respectively. The C-terminal residues of both isoforms are identical, and both isoforms are biologically equipotent in the activation of the PrRP receptor. It has been demonstrated that PrRP can be shortened to PrRP8-20 without any loss of activity at the wildtype (wt) receptor and that these thirteen C-terminal residues are the minimum number of amino acids essential for full activation of the PrRP receptor. 11 Little is known about the mode of binding and activation of the PrRP receptor by PrRP, especially on a structural level. This is likely due to the lack of functional antagonists of the PrRP receptor and difficulties in structure determination of GPCRs. Here, we investigate the importance of the peptide's secondary structure for receptor activation. Nuclear magnetic resonance (NMR) spectroscopy had previously been used to determine the structure of PrRP20 in micelles. 12 A second study reported an image of a PrRP20 structural model without revealing experimental details, such as solvent conditions or a list of NMR restraints. 13 Neither study made the models publicly available. However, D'Ursi, et al. provided a list of sparse chemical shifts and nuclear Overhauser effect distance restraints (NOEs). 12 We employed ROSETTANMR [14] [15] [16] to generate an ensemble of peptide conformations that is consistent with newly obtained circular dichroism (CD) spectroscopy data and this set of NMR restraints. Further, we identified receptor mutants for which PrRP8-20 displays a significant loss in activation compared to PrRP20. By comparing the activation ability of four PrRP analogs on two receptor mutants, we can distinguish between direct effects on ligand-receptor interaction and indirect effects that result from alteration of peptide helicity. This combined computational-experimental approach allows us to understand the interaction of PrRP and its receptor on a molecular level.
RESULTS
Previous NMR Studies of C-Terminally Amidated PrRP20 Reveal a Helical C-Terminal Region ROSETTANMR [14] [15] [16] was employed to construct a model of Cterminally amidated PrRP from 38 previously reported interproton distances (NOEs) and 13 Ha chemical shifts, which were collected at pH 5.5 in 100 mM sodium dodecyl sulfate, or SDS (Supporting Information Tables S1 and S2) . 12 These NMR data were obtained for PrRP20. We chose to construct structural models for residues 8-20 of PrRP20 because the structural restraints cover mainly these residues, implying that residues 1-7 are conformationally flexible. However, because only a partial dataset was available, the herein discussed peptide model ensemble serves only as a starting point for further structural characterization of the PrRP/ PrRP receptor interaction. The generated models were further confirmed with CD spectroscopy (see Structural Investigations of PrRP by CD Spectroscopy Studies Indicate a Decreased Helical Propensity for . The NOEs and chemical shifts occurring within residues 8-20 are indicative of a combination of a-and 3 10 -helical secondary structure. The presence of aN(i,i 1 2) NOEs is often associated with i(i 1 3) hydrogen bonding characteristic of 3 10 -helices. Further, the ratio of ab(i,i 1 3) to aN(i,i 1 3) NOEs, as well as the lack of aN(i,i 1 4) NOEs, support the idea that the peptide exists in an equilibrium of a-and 3 10 helix in SDS micelles [17] [18] [19] ). An ensemble of twenty low-energy models of the PrRP20 residues 8-20 consistent with the NMR data obtained for the full-length peptide was generated and deposited in the Protein Model Database 20 ( Figure 1 ; Supporting Information; PM ID: 0078404).
Secondary Structural Analysis of PrRP20 Models Implies a Conformational Equilibrium
The final ensemble of PrRP models was chosen based on the models' overall energy according to the ROSETTANMR The twenty lowest-energy models resulting from full-atom refinement that had a ROSETTANMR restraint score 1.0 ROSETTA energy unit (REU). Briefly, 10,000 models were de novo folded in the presence of 38 distance restraints. Energetically favorable models that satisfied the NMR data were then refined to atomic detail using the same 38 restraints. Notice that all three arginine residues are on one side of the amphipathic helix.
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full-atom soluble protein scoring function, 21 as well as their agreement with the NMR distance restraints for the fulllength peptide (Supporting Information Tables S3 and S4) . 12 Define Secondary Structure of Proteins (DSSP) 22, 23 analysis
indicates that these models are mainly a-helical, especially between residues 10-13 and 15-19, with the other residues being coil or bend/turn (Figure 2A ). Note the often-observed non-ideal helical character around residue I 14 . This is likely due to the inability of the nitrogen of P 16 to hydrogen bond with the carbonyl oxygen on R 12 (distance 5 4.98 6 0.27 Å ), thus disrupting the hydrogen bond between G 13 and V
17
(distance 5 5.00 6 0.26 Å ) ( Figure 2B ). The models exhibit u and w angles (torsion angles around the N-C a bond and the C a -C bond, respectively) characteristic of both a-and 3 10 -helix, where a-helices have an average u angle of 2578 and an average w angle of 2708. 3 10 -helicies typically have average u angles of approximately 2498 and average w angles of 2268 ( Figure 2C ). [24] [25] [26] Interestingly, residues 10-13 appear to usually form an a-helical turn, but they can also adopt a 3 10 -helical structure (Supporting Information Table  S5 , Models 10 and 11). Furthermore, the DSSP secondary structure analysis reveals that $15% of all models de novo folded and refined with ROSETTANMR contained both a-and 3 10 -helical conformations, but the majority of models were primarily a-helical (Supporting Information Figure S1 ). These results match D'Ursi, et al.'s NOE data, which support an unambiguously a-helical C-terminal region (residues [15] [16] [17] [18] [19] , whereas the N-terminus of PrRP20 appeared to be in a conformational equilibrium, fluctuating between a-helix, 3 10 To elucidate the structural and functional requirements for PrRP20 binding and receptor activation, a set of PrRP analogs was synthesized and characterized (Table I) . Because the C-terminal region of the peptide is presumably responsible Further, the CD spectrum of PrRP8-20 in phosphate buffer also suggests a primarily disordered peptide; the slight maximum at $228 nm suggests the presence of some polyproline II helix conformation as well 27, 28 ( Figure 3A , left panel). Interestingly, according to the spectra of PrRP20 and PrRP4-20, the peptides may contain some ordered secondary structural character, including 3 10 -helix (Table II) ; note the deep minima at $205 nm and the shoulder at $222 nm. This is also supported by the peptides' R 222/208 values of 0.46 6 0.01 and 0.37 6 0.02, respectively. According to Toniolo, et al., this ratio is expected to be between 0.15 and 0.40 for 3 10 -helical peptides and $1.0 for a-helical peptides.
29,30
Next, we investigated the peptide in solvents mimicking the partially apolar membrane environment while retaining a certain biocompatibility. We will label the three experimental conditions as ''aqueous,'' ''SDS,'' and ''TFE'' throughout the remainder of the manuscript. For PrRP20 tested in 100 mM SDS solution, a well-known membrane mimicking detergent, we observe a maximum at 195 nm, a minimum at 205 nm, and a shoulder around 222 nm ( Figure 3B , left panel); the latter two spectral features are indicative of a 3 10 -helical component to the conformational ensemble. The characteristic minima for solely a-helically structured peptides are at 208 and 222 nm. 31 However, the R 222/208 value of 0.54 6 0.01 is higher than expected for a pure 3 10 -helix. We therefore conclude that, in SDS, PrRP20 adopts a partially a-helical conformation, with 3 10 -helix and other secondary structural components also being present. Similar observations were observed for PrRP4-20 (R 222/208 5 0.63 6 0.01). The CD spectra of PrRP14-20 has 3 10 -helix character, (R 222/208 5 0.40 6 0.05), whereas PrRP8-20 appears to remain primarily coil/poly-proline II helix under these conditions ( Figure 3B , left panel; Table II ). Fluorinated alcohols, such as trifluoroethanol, or TFE, are organic solvents that induce environmental constrains; TFE/ water mixtures exhibit helix-inducing biocompatible conditions. For CD spectroscopy of PrRP20 and PrRP4-20 measured in TFE/water, R 222/208 values of 0.68 6 0.01 and 0.65 6 0.01, respectively, were calculated. These values support the assumption that the peptides are primarily a-helical (Table  II) . Indeed, in TFE/water, the helical content of the fulllength peptide increased, with the spectrum exhibiting deep minima at 208 and 222 nm. These minima are more pronounced than those seen in the CD spectra obtained in SDS micelles. In contrast, the spectra of PrRP8-20 and PrRP14-20 in TFE are more reminiscent of that of a mixture of helices with a strong 3 10 -helix component. Both peptides exhibit a minimum at $202 nm and a shoulder at about 220 nm ( Figure 3C , left panel). Further, the R 222/208 values for these peptides were 0.45 6 0.08 and 0.54 6 0.03, respectively (Table II). The experiments in TFE were repeated at various pHvalues and temperatures of 258, 378, and 508 for both PrRP20 and PrRP8-20 in order to confirm that the spectra were largely independent of these parameters ( Figure 4 ).
Single-Substituted PrRP20 Analogs Do Not Exhibit Different Secondary Structure from wt PrRP20
Single alanine mutants of PrRP20 at R 15 , R 19 , and F 20 positions have been previously implicated with peptide activity 1, 11, 13 and were also tested here. Note that the highly conserved C-terminal residues, R 19 and F, 20 make PrRP a , and A 20 PrRP20). CD spectra are represented in mean residue ellipticity, measured in 40 lM peptide in 10 mM phosphate buffered solution at pH 7 and 228C. (A) CD spectra measured without additives, (B) in 100 mM micellar SDS solution, and (C) 25% TFE-containing solution. All curves were calculated with the baseline corrected for buffer effects.
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member of the RF-amide peptide family. To study the influence of the conserved RF-amide motif and the impact of charged amino acids at the hydrophilic side of the helix on the overall peptide structure, we performed CD spectroscopy on A Table II ). Interestingly, all tested conditions (aqueous, SDS, TFE) resulted in almost identical CD spectra for PrRP20 and all alanine mutants.
Although CD spectroscopy is not sensitive enough to identify small, local rearrangements in the peptide, we conclude that the modified single side chains at positions 15, 19, and 20 have no impact on the overall secondary structure of the peptide. Therefore, any loss of activity when interacting with the receptor results from a change in the interaction with the receptor, rather than a change in structure or dynamics of the peptide (see the following section).
Binding to and Activation of the wt PrRP Receptor is Primarily Mediated by Direct Interactions with PrRP
To evaluate the biological relevance of the PrRP20 analogs, binding and signal transduction capabilities were investigated in COS-7 cells transiently transfected with the PrRP receptor. In a displacement assay with the wt PrRP receptor using 1 nM N[propionyl 3 H]hPrRP20, an IC 50 -value of 4.1 6 0.7 nM was obtained, where IC 50 is the inhibition concentration of the ligand at half maximum biological activity of the receptor. A dissociation constant, or K D , value of 0.58 nM was computed using established methods. 32 The activity of PrRP20 was determined using an IP, or inositol phosphate, accumulation assay (see Materials and Methods) and resulted in an EC 50 -value of 2.2 6 0.3 nM (Table III) . The EC 50 is the effective concentration of the ligand at half maximum biological activity. The radioligand binding assays revealed IC 50 -values of 1.2 6 0.1 nM and 7 6 1.8 nM for PrRP4-20 and PrRP8-20, PrRP20 had a lower impact in IP accumulation. The EC 50 -values were only 9-and 22-fold increased compared to the unmodified PrRP20, respectively. Apart from PrRP14-20, which exhibited a 6-fold increased EC 50 -value of 14 6 2 nM, the truncated analogs, PrRP4-20 and PrRP8-20, showed wt-like signaling properties (Table III) .
PrRP8-20's is Unable to Activate Extracellular Loop 1 PrRP Receptor Mutants
Next, we investigated the interaction of PrRP8-20 and PrRP20 with different receptor mutants. Because extracellular loop 1, referred to as EL1 for the remainder of this discussion, of other peptide receptors is known to be important for interactions with the ligands, 33, 34 we assumed that charged or aromatic amino acids of the EL1 region may be involved in ligand recognition via hydrophobic, ionic, or p-cationic interactions. Therefore, we substituted all such residues between position 2.64 and 2.73 to alanine (Table IV) further right-shifted concentration-response curve when compared to activation with PrRP20 ( Figure 5 ) and hence elevated EC 50 -values (434 6 96 nM and 2119 6 390 nM, respectively, Table IV ). We hypothesized that changes in structure or dynamics of the ligand might cause this difference in receptor activation, as mutation/deletion studies of residues 1-7 did not suggest a direct contact point between this part of the ligand and the receptor.
DISCUSSION

Structure-Activity/Affinity Studies are Needed to Understand PrRP Receptor Activation
The objective of this study is to better understand the structural determinants of PrRP receptor activation, an important milestone towards the development of potent small-molecule agonists given the increasing prevalence for the physiological role of PrRP20 and its receptor. 35 This is a formidable challenge, as structure-activity relationship studies of the PrRP/PrRP receptor system are rare. Initial investigations of the truncated PrRP20 analogs, PrRP4-20 and PrRP8-20, exhibited wt-like binding and IP accumulation behavior. Further, in our assay system, a reduced affinity of the full agonist, PrRP14-20, is in accordance with recent studies. 1, 11 We hypothesized that the structure and dynamics of PrRP's interaction with the receptor is altered through the truncation, rather than single point mutation, of the peptide. This hypothesis was tested through CD and NMR spectroscopic studies that assert the secondary structure of the peptide. To mimic the amphipathic environment of the peptide when it is interacting with the receptor, the additives SDS and TFE were used.
36,37
CD and NMR Spectroscopic Studies Support a Mainly Helical Peptide Conformation
While SDS is an accepted membrane mimic, TFE mainly induces secondary structure. 38 SDS micelles provide a nonisotropic, apolar environment in which the membrane interactions of the biomolecules can be investigated. A molecular dynamics study has shown that, in a TFE/water mixture, the organic cosolvent aggregates around the peptide, forming a matrix that partly excludes water. This process stabilizes the secondary structure, as the formation of proximate interactions is assisted. 38 We suggest that, to some extent, both solvents mimic the membrane surface thought to contribute to the transition of the peptide from a random coil to a helical conformation that is recognized by the receptor. 39 Accordingly, we assume that PrRP20 will adopt a conformation more similar to the bioactive form when interacting with these solvents. According to our CD spectroscopic studies, the single mutant PrPR20 analogs, A and PrRP4-20, while exhibiting some 3 10 -helical character in phosphate buffer, became increasingly a-helical in SDS and TFE. In contrast, PrRP8-20 appears to be primarily disordered, or nascent helix at most, in SDS. Its 3 10 -helix component does increase in TFE, but it is almost undoubtedly not an a-helix, unlike the full-length peptide. Our results indicate that the peptide length of PrRP is a significant determinant in its ability to form an a-helix. It appears that the N-terminus, which exhibits increased flexibility, is nevertheless involved in stabilizing the C-terminal helical segment. Even though PrRP8-20 fully activates the wt receptor ( Figure 5) , it shows little a-helical propensity in SDS and TFE when compared to PrRP20. Earlier CD studies could not clearly distinguish between 3 10 -and a-helical peptide structures, which were investigated using a set of seven peptides ranging in length from 10 to 21 amino acid residues. 40 In contrast, a recent report describes the standard CD spectrum of a 3 10 -helial octapeptide. 29 Indeed, evidence of this combination of coil and helical secondary structure can be seen in the CD spectra of the PrRP analogs, which were collected in SDS micelles or TFE ( Figure  3 , left panel). The shape of PrRP20 and PrRP4-20 in TFE fits to the formerly described spectrum for an a-helical pep- 
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tide. 29, 41 In the case of PrRP8-20, the membrane-mimicking SDS micelles are not capable of inducing a-or 3 10 -helical conformation, in contrast to the longer peptides. For the analogs PrRP8-20 and PrRP14-20, the shape of the curves is altered, having a lower Cotton effect and different minima. The combination of CD and computational modeling results, as well as analysis of the 13 C-terminal residues of PrRP20, imply a structural model for the full-length peptide, in which the peptide forms an extended helix. According to a secondary structure analysis of the final ensemble with DSSP, 22, 23 it appears that, in most low-energy ROSETTANMR models, 8-9 of the 13 residues tend to be a-helical. The ideal helical geometry is broken around residue I
14
. This is expected due to the lack of ideal a-helix hydrogen bonding between R 12 and P
16
, as well as between G 13 and V
17
. In our model, the helix bulges and bends in this area. Interestingly, the helical character of the models can either consist of all ahelix or a combination of approximately half a-helix and half Table S2 ). According to these data, PrRP20 in solution is not solely a-helical, nor is it completely random coil.
The presence of potential 3 10 -helical character in the PrRP20 models may be a result of its amphipathic nature and the fact that the NMR data were also collected in SDS micelles at high PrRP20 concentration (0.5215 mM). 12 Indeed, there is evidence that amphipathic helices can assume extended (often 3 10 ) helical conformations in certain mediums, such as in detergent micelles. 42, 43 Remarkably, it has been proposed that the R 1 xxR 2 xxR 3 xxR 4 xxR 5 xxR 6 motif in the Kv1.2-and Kv2.1-chimeric potassium ion channel structures form an extended 3 10 -helix, which allows the arginine residues to sit on the same side of the helix. 44, 45 This is also often observed in our models of PrRP, which contains three arginine residues in an R 1 xxR 2 xxxR 3 motif. Further, the conformational equilibrium between nascent, a-, and 3 10 -helix is seen in other systems. Another neuropeptide, the galanin-like peptide (GALP), has been shown to be only loosely ordered in solution, but in TFE, it forms stable helical structures. Indeed, its CD spectrum resembles that of a 3 10 -helix and is similar to our CD spectra obtained for PrRP20 in buffer and SDS and PrRP8-20 in TFE. 46 The 16 amino acid sequences of the C-terminal helices of two bacterial cytochromes were synthesized and characterized by CD and NMR spectroscopy. These peptides' spectra also imply a dynamic equilibrium between a-and 3 10 -helix. 47 It is possible that this conformational equilibrium is due to folding and unfolding of the free (as opposed to receptorbound) peptide in solution; the 3 10 -helix is often considered to be a kinetic intermediate when forming an a-helix from coil. To further elucidate the role of N-terminal PrRP20 truncations with respect to ligand binding, we chose to study the EL1 of the receptor because this region is known to be a prominent agonistic binding region in GPCRs. With respect to receptor activation, the alanine scan of selected amino residues within EL1 of the PrRP receptor identified the aromatic residues Y 2.64 and W 2.71 to be important. Both residues might contribute to a hydrophobic cluster, as described for the neurotensin receptor 1, where EL1 is described to be stabilized by p-stacking clusters and was proved to be important for agonist binding. 33 In A PrRP receptor. Combining these findings, we expect that the receptor assists PrRP in forming its bioactive a-helical conformation. This conformation is induced by the wt receptor for PrRP20, as well as PrRP8-20, even though its a-helical propensity is reduced due to the missing residues 1-7. However, the mutations Y 2.64 A and W 2.71 A partially impair the helix-inducing capabilities of the receptor. This leads to a reduced activity for both PrRP20 and PrRP8-20. The reduced helical propensity of PrRP8-20 results in a more dramatic loss of activity for its interaction with the mutant receptors. The results obtained from our structure-activity and spectroscopic studies suggest that Y 2.64 and W 2.71 provide part of the hydrophobic framework that induces helicity in the ligand.
CONCLUSION
The C-terminal segment of PrRP20 was shown by NMR and CD spectroscopy to adopt a combination of a-and 3 10 -helical conformation in SDS micelles and becomes primarily ahelical in TFE. Moreover, the decreased stability of the helical segment generated by shorter PrRP20 analogs resulted in reduced biological activity. In contrast, single amino acid replacement of crucial residues led to significantly decreased binding and activity, while the overall peptide structure was maintained. With respect to future structure/activity studies, we disclose that a stable C-terminal a-helix facilitates the ligand recognition by its receptor. By making a three-dimensional structure of PrRP publicly available, the structurefunction studies can now be performed more effectively with the ability to look at the structure of the peptide itself. Additionally, the identification of the important residues Y 
MATERIALS AND METHODS
Structure Determination Using ROSETTANMR
Details of the ROSETTANMR protocol have been described elsewhere. [14] [15] [16] 55 Briefly, torsion angle restraints were derived from 13 H a chemical shift values using TALOS 56 (Supporting Information  Table S1 ). Further, 28 distance restraints obtained from NOEs between backbone hydrogen atoms were used and were classified as either ''strong'' (proton-proton distance 3 Å ) or ''weak'' (protonproton distance 5 Å ) (Supporting Information Table S2 ). A library of overlapping 3-and 9-amino acid peptides spanning residues 8-20 of PrRP20 were generated from coordinates found in the PDB. During folding, an additional 10 NOEs resulting from resonances between side chain protons-again, classified as ''strong'' ( 3 Å ) or ''weak'' ( 5 Å )-were included as distance restraints (Supporting Information Table S2 ).
Ten thousand backbone-only structural models were generated using ROSETTANMR's de novo folding algorithm. 57, 58 From these original models, the 10% most energetically favorable models (according to the ROSETTANMR scoring function) were refined to atomic detail, including the addition of the functionally obligatory C-terminal amide functional group. The ROSETTANMR energy function includes solvation, electrostatic interactions, van der Waals attraction/repulsion, and hydrogen bonding, all of which were included in the assessment of overall structural quality. 21, 57 The 20 conformations that fulfill the distance restraints with deviations smaller than 1 Å and have the lowest ROSETTANMR energies constitute a conformational ensemble that is consistent with the published NMR data and is physically plausible according to the ROSETTANMR energy function (Figure 1 ).
Peptide Synthesis
Human PrRP20, PrRP14-20, PrRP8-20, PrRP4-20, A 15 PrRP20, A 19 PrRP20, and A 20 PrRP20 were synthesized by automated multiple solid-phase peptide synthesis on the multiple peptide synthesizer Syro II (MultiSynTech GmbH, Witten, Germany) using the orthogonal Fmoc/tBu strategy. 59 Rink amide resin (30 mg, resin loading 0.6 mmol g 21 ), obtained from Iris Biotech GmbH (Marktredwitz, Germany), was used to produce the C-terminally amidated peptides. Na-Fmoc (N-(9-fluorenyl)methoxycarbonyl)-protected amino acids were purchased from Iris Biotech GmbH (Marktredwitz, Germany). The protected amino acids (10 eq) were dissolved in 0.5 M tert-butyl alcohol in dimethylformamide and activated in situ by diisopropylcarbodiimide (DIC) (10 eq). Removal of protection groups and final cleavage of the peptide from the resin was accomplished simultaneously using a cleavage cocktail consisting of either trifluoroacetic acid (TFA)/ thioanisole/1,2-ethanedithiol (90:7:3 v/v/v) for tryptophane-containing peptides or TFA/thioanisole/p-thiocresol (90:5:5 v/v/v) within 3 h.
Peptide purification was achieved by preparative reversed-phase HPLC (Vydac RP18-column, 22 3 250 mm, 10 lm/300 Å , Grace, Deerfield, IL or Phenomenex Jupiter 10 U Proteo column, 250 3 21.20 mm, 90 Å , Aschaffenburg, Germany) using 0.08% TFA in either acetonitrile or methanol and 0.1% TFA in water as the eluting system to yield homogenous peptides of [90% purity. The peptides were characterized by mass spectrometry using matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry on an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bremen, Germany). Analytical reversed-phase HPLC was performed on a Vydac RP18-column (4.6 3 250 mm; 5 lm/300 Å ; Grace, Deerfield, IL) by using two different linear gradient systems of 0.1% (v/v) TFA in water and 0.08% (v/v) TFA in either acetonitrile or methanol. Analytical data are summarized in Table I .
Cloning of the RF-Amide Peptide Receptors in Eukaryotic Expression Vectors
To obtain genomic DNA from SMS-KAN cells, approximately 1 million cells were digested overnight at 558C with 500 lL lysis buffer (1M NaCl, 20% SDS, 0,5M EDTA, 1M Tris, pH 8.5) containing 50 lg proteinase K (Promega, Mannheim, Germany). Genomic DNA was extracted using phenol/chloroform and precipitated from the aqueous phase with isopropanol, washed with ethanol, and then dissolved in water. The coding sequence of the human PrRP receptor was obtained by PCR amplification from the genomic DNA of SMS-KAN cells. Cloning of cDNA into the eukaryotic expression vector pEYFP-N1 (Clontech, Heidelberg, Germany) C-terminally fused to EYFP was performed, using the XhoI and BamHI site to result in the constructs phPrRP receptor_EYFP-N1. Mutations were introduced with the QuikChange TM site-directed mutagenesis method (Stratagene). The residues are numbered according to the Activity of PrRP Correlates with its Helicity 323 system of Ballesteros and Weinstein. 60 The correctness of all constructs was confirmed by sequencing of the entire coding sequence.
Cell Culture
Cell culture material was supplied by PAA Laboratories GmbH (Pasching, Austria). COS-7 cells (African green monkey, kidney) were cultured in Dulbecco's Modified Eagle's Medium containing 10% (v/v) heat-inactivated fetal calf serum (FCS), 100 units/mL penicillin, and 100 lg/mL streptomycin. SMS-KAN cells (human neuroblastoma cells) were maintained in nutrient mixture Ham's F12/Dulbecco's modified Eagle medium (1:1) with 15% (v/v) FCS, 4 mM glutamine, 0.2 mM non essential amino acids, 10 units/mL penicillin, and 10 lg/mL streptomycin. Cells were grown as monolayers at 378C in a humidified atmosphere of 5% CO 2 and 95% air.
Signal Transduction Assay
For signal transduction (inositol phosphate accumulation) assays, COS-7 cells were seeded into 24-well (1.0 3 10 5 cells/well) or 48-well plates (6.0 3 10 4 cells/well) and transiently transfected with 0.4 lg plasmid DNA using 1.2 lL metafectene (Biontex Laboratories GmbH, Martinsried/Planegg, Germany). Incubation with 2 lCi/mL [ 3 H]myo-inositol (GE Healthcare Europe GmbH, Braunschweig, Germany) in DMEM supplemented with 10% (v/v) FCS was performed 1 day after transfection and 16 h before stimulation. Labeled cells were washed once and stimulated with increasing concentrations of each peptide for 1 h at 378C in DMEM containing 10 mM LiCl (Sigma-Aldrich, Taufkirchen, Germany), as described previously. 59, 61 Receptor stimulation and IP accumulation were stopped by aspiration of medium, and cell lysis was performed with 0.1M NaOH (24-well plate: 150 lL/well; 48-well plate: 100 lL/well) for 5 min. After neutralizing with 0.2 M (24-well plate: 50 lL/well) or 0.13 M (48-well plate: 50 lL/well) formic acid, IP dilution buffer (5.0 mM Na-borate 1 0.5 mM Na-EDTA; 24-well plate: 1 mL/well; 48-well plate: 750 lL/well) was added to each well.
Intracellular IP levels were determined by anion-exchange chromatography on Bio-Rad AG 1-X8 resin, either by manual pipetting or using an automated pipetting robot system (USK-UTZ GmbH, Limbach-Oberfrohna, Germany). Radioactivity was measured by a scintillation counter (Win Spectral 1414 Liquid Scintillations Counter Wallac). 62, 63 Data were analyzed with the GraphPad Prism 3.0 program (GraphPad Software, San Diego, CA), and EC 50 -values were obtained from concentration-response curves. The EC 50 -determinations were performed in duplicate, and signal transduction assays were repeated at least twice independently.
